American journal of physiology. Endocrinology and metabolism

How glucagon-like peptide-1 signals in the brain's reward area reduce food intake through AMPA/kainate receptors

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Intra-VTA injections of the GLP-1R agonist exendin-4 (Ex-4) reduced palatable high-fat food intake in rats primarily by reducing meal size.

  • GLP-1 receptor activation in the ventral tegmental area is linked to decreased food intake.
  • The reduction in meal size is associated with glutamatergic signaling involving AMPA/kainate receptors, but not NMDA receptors.
  • GLP-1 receptors within the VTA may play a role in the effects of systemically administered Ex-4 on food intake and body weight.
  • Ex-4 administration led to a rapid increase in tyrosine hydroxylase levels in the VTA, indicating modulation of dopaminergic signaling.
  • Electrophysiological data showed increased frequency of AMPA-mediated currents in VTA dopamine neurons after Ex-4 treatment.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Aug '11
The liver-related vagus nerve branch is not needed for glucagon-like-peptide-1 to reduce blood sugar and food intake
cited by 75 papers
research support, n.i.h., extramural
Dec '11
GLP-1 neurons in the brainstem send signals to reward areas to regulate eating
top 10% journal
cited by 423 papers
research support, n.i.h., extramural
Jun '11
Appetite reduction by liraglutide and exendin-4 involves GLP-1 receptors in both the body and brain
top 10% journal
cited by 314 papers
research support, n.i.h., extramural
Feb '19
Glucagon-like peptide-1 receptors in specific brain areas influence alcohol-related behaviors in rodents
top 10% journal
cited by 76 papers
research support, non-u.s. gov't
Jun '14
Signals in a brainstem area reduce hunger and motivation to eat
cited by 96 papers
research support, n.i.h., extramural
Aug '17
Control of Eating and Reward by a Thalamus Area Involving Glucagon-Like Peptide-1 Receptors
top 5% journal
cited by 104 papers
journal article

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
yesterday7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
1 week ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
2 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
3 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
4 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
5 weeks ago7 studies
issue #38
Two-thirds of patients kept weight off after stopping GLP-1 drugs
6 weeks ago7 studies
issue #36
Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months
8 weeks ago7 studies
issue #35
Semaglutide linked to 2.5x higher risk of sudden vision loss
9 weeks ago7 studies
issue #34
Tirzepatide users had 18.4% weight loss vs 11.9% with semaglutide in head-to-head trial
10 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief